Medical Industry Equipment With Microbiome Therapeutics For Clinical Trials Applications
-
Manufactured by Finch Therapeutics Group, Inc.based in USA
FIN-211 is an orally administered, Enriched Consortia product candidate designed to address both the gastrointestinal (GI) and behavioral symptoms of ASD. ASD is a behaviorally defined condition characterized by difficulties with interpersonal interaction, communication, and repetitive or restrictive patterns of behavior and activities. A subset of individuals with ASD experience significant GI ...
-
Manufactured by Finch Therapeutics Group, Inc.based in USA
CP101, an orally administered, Complete Consortia product candidate in late-stage clinical development for the prevention of recurrent C. difficile infection is also being developed for the treatment of chronic HBV. Chronic HBV infection occurs when the initial immune response fails to clear the virus, and may result in inflammation of hepatocytes, and complications including cirrhosis, liver ...
-
Manufactured by Finch Therapeutics Group, Inc.based in USA
In collaboration with Takeda Pharmaceuticals, we are developing FIN-524 and FIN-525, orally administered, Targeted Consortia product candidates designed for the treatment of ulcerative colitis (UC) and Crohn’s disease (CD), respectively. UC and CD are the two most common types of IBD, an autoimmune condition that causes inflammation of the gastrointestinal (GI) ...
-
Manufactured by Finch Therapeutics Group, Inc.based in USA
Our lead product candidate, CP101, is an orally administered, Complete Consortia product candidate initially targeting the prevention of recurrent CDI. The Centers for Disease Control and Prevention considers CDI to be one of the top three most urgent antibiotic resistant threats and the most common cause of healthcare associated infection in the United ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you